Browsing of Anticancer Drugs

This module allows users to browse anticancer drugs in CancerDR. This page summarizes the drugs with different descriptors like pI, Volume, Hydrogen Bond Acceptor, Hydrogen Bond Donor, Structure link, molecular targets. For more information, please click Help

Drug Name	Pubchem ID	Clinical Status	Molecular Targets	Number of Targets	Target Class	Chemical Formula	Molecular Weight	Polarizability	pI	Volume	HBA	HBD	Cells Tried

681640	10384072	Experimental	WEE1, CHK1	2	Ser Thr Kinase	C20H11ClN2O3	362.766	36.39		282.6	3	3	540
17AAG	6505803	Phase III	HSP90AA1, HSP90AB1, HSP90AB4P, HSP90B1,	5	Stress pathway,	C31H43N3O8	585.6884	61.68	5.85	550.26	8	4	1076
A443654	10172943	Experimental	AKT1, AKT2, AKT3	3	Ser Thr Kinase	C24H23N5O	397.4723	44.62	11.61	356.81	4	3	358
A770041	9549184	Experimental	SRC	1	Tyrosine kinase	C34H39N9O3	621.732	68.86	9.67	559.34	8	2	560
ABT263	24978538	Phase I	BCL2, BCLXL, BCLW	3	Apoptosis	C47H55ClF3N5O6S3	974.613	101.39	6.88	837.13	10	2	574
ABT888	11960529	Phase I	PARP1, PARP2	2	DNA repair	C13H16N4O	244.2923	26.57	9.72	220.62	3	3	503
AEW541	11476171	Experimental	IGF1R	1	Apoptosis	C27H29N5O	439.5521	50.69		405.01	5	1	479
AG014699	9931953	Phase I, Phase II	PARP1, PARP2	2	DNA repair	C19H21FN3O5P	421.3593	37.14	11.39		2	3	557
AICAR	65110	Phase II	PRKAA1,	1	Metabolism	C9H15N4O8P	338.2112	28.95	2.99	256.52	9	6	562
AKTinhibitorVIII	16218954	Phase II	AKT1, AKT2, AKT3	3	Ser Thr Kinase	C36H32F3N7O4	683.679	61.82	9.76		5	2	667
AMG706	11667893	Phase I, Phase II	VEGFR1, VEGFR2, RET, KIT, PDGFRA, PDGFRB	6	Receptor Tyrosine kinase	C22H23N5O	373.4509	39.38	9.05	341.74	5	3	560
AP24534	24826799	Phase I	ABL1	1	Tyrosine kinase	C29H27F3N6O	532.5595	56.18	9.67	461.32	5	1	667
AS601245	11422035	Experimental	JNK1, JNK2, JNK3	3	Ser Thr Kinase	C20H16N6S	372.446	39.38	8.38	317.96	6	2	661
ATRA	444795	Approved	RXRB, RXRG, RAR1	3	Transcription,	C20H28O2	300.4351	36.62		312.36	2	1	573
AUY922	10096043	Phase II	HSP90AA1, HSP90AB1, HSP90AB4P, HSP90B1,	5	Apoptosis	C26H31N3O5	465.5414	50.83	7.32	425.03	7	3	661
Axitinib	6450551	Approved	PDGFRA, PDGFRB, KIT, VEGFR2	4	Receptor Tyrosine kinase	C22H18N4OS	386.47	42.67	9	334.27	3	2	576
AZ628	11676786	Experimental	BRAF	1	Receptor Tyrosine kinase	C27H25N5O2	451.5197	48.23	8.81	410.75	5	2	354
AZD0530	10302451	Phase II	SRC, ABL1	2	Tyrosine kinase	C27H32ClN5O5	542.026	57.25	9.94	472.15	10	1	865
AZD2281	23725625	Phase I	PARP1, PARP2	2	DNA repair	C24H23FN4O3	434.4628	43.54	5.96	375.65	4	1	557
AZD6244	10127622	Phase II	MAP2K1, MAP2K2	2	Ser Thr Kinase	C17H15BrClFN4O3	457.681	40.73	7.79	323.52	5	3	1033
AZD6482	44137675	Phase I	PI3KCB, PI3KC2B	2	Apoptosis	C22H24N4O4	408.4504	42.77	3.32	364.43	7	2	667
AZD7762	1152667	Phase I	CHK1, CHK2	2	Ser Thr Kinase	C18H21FN4O2S	376.448	39.45	12.28	324.29	4	4	574
AZD8055	25262965	Phase I	MTOR	1	Ser Thr Kinase	C25H31N5O4	465.5447	51.44	8.89	425.97	9	1	553
BAY613606	16760671	Experimental	SYK	1	Tyrosine kinase	C20H23ClN6O5	462.887	40.66	9.05		7	2	661
Bexarotene	82146	Approved	RXRA, RXRB, RXRG	3	Transcription	C24H28O2	348.4779	40.89		349.49	2	1	538
BI2536	11364421	Phase II	PLK1, PLK2, PLK3	3	Ser Thr Kinase, Mitosis	C28H39N7O3	521.6544	59.67	10	491.84	8	2	359
BIBW2992	44569596	Phase III	EGFR, ERBB2	2	Receptor Tyrosine kinase	C25H26ClFN4O3	484.95	50.8	10.7	417.7	6	2	576
Bicalutamide	2375	Approved	AR	1	Metabolism	C18H14F4N2O4S	430.373	36.68	3.95	332.45	5	2	661
BID1870	25023738	Experimental	RSK1, RSK2, RSK3, PLK1, AURKB	5	Ser Thr Kinase	C19H23F2N5O2	391.415	39.81	6.59	342.82	6	2	573
BIRB0796	156422	Experimental	MAPK11, MAPK12, MAPK13, MAPK14, JNK2	5	Ser Thr Kinase	C31H37N5O3	527.6572	58.53	9.11	495.63	5	2	573
Bleomycin	5460769	Approved	DNAdamage	1	DNA repair	C55H84N17O21S3	1415.552	140.88	11.41	1211.93	28	20	661
BMS509744	20635522	Experimental	ITK	1	Tyrosine kinase	C31H39N5O4S2	609.802	67.99	9.83	555.7	6	2	359
BMS536924	10390396	Experimental	IGF1R	1	Apoptosis	C25H26ClN5O3	479.959	51.4	8.35	409.95	8	4	359
BMS708163	46883536	Phase II	Gamma-secretase	1	Cell cycle	C20H17ClF4N4O4S	520.885	44.02	5.28	394.32	5	1	358
BMS754807	24785538	Phase I	IGF1R	1	Ser Thr Kinase	C23H24FN9O	461.4948	48.11	8.81	389.5	7	3	482
Bortezomib	387447	Approved	Proteasome	1	Cell cycle	C19H25BN4O4	384.237	40.25	6.13	364.25	6	4	661
Bosutinib	5328940	Phase I	ABL1, SRC, TEC	3	Tyrosine kinase	C26H29Cl2N5O3	530.446	56.2	11.96	460.51	8	1	354
Bryostatin	5280757	Phase II	PRKCA, PRKCB, PRKCD, PRKCE, PRKCG, PRKCH	10	Angiogenesis, Apoptosis	C47H68O17	905.0326	96.01	3.96	847.67	12	4	574
BX795	10077147	Experimental	TBK1, PDK1, IKBKE, AURKB, AURKC	5	Ser Thr Kinase	C23H26IN7O2S	591.468	56	8.96	434.87	6	4	661
Camptothecin	104842	Approved	TOP1,	1	DNA repair	C22H20N2O5	392.4046	41.43	6.79	336.23	5	2	667
CCT007093	NA	Experimental	PPM1D	1	Stress pathway	C15H12OS2	272.385	29.12		229.13	1	0	468
CCT018159	NA	Experimental	HSP90	1	Stress pathway	C17H15ClN2O3	330.766	33.72	5.27	271.18	5	3	358
CEP701	126565	Phase II	FLT3, JAK2, NTRK1, RET	4	Tyrosine kinase	C26H21N3O4	439.4626	46.9	5.38	364.76	4	3	661
CGP082996	24825971	Experimental	CDK4	1	Ser Thr Kinase	C27H32N6O	456.5826	53.07	9.5	426.41	6	4	482
CGP60474	644215	Experimental	CDK1, CDK2, CDK5, CDK7, CDK9	5	Cell cycle	C18H18ClN5O	355.821	38.53	9.22	307.17	6	3	470
CHIR99021	9956119	Experimental	GSK3B	1	Tyrosine kinase	C22H18Cl2N8	465.338	48.14	9.46	378.71	7	3	576
CI1040	6918454	Phase II	MAP2K1, MAP2K2	2	Ser Thr Kinase	C17H14ClF2IN2O2	478.66	39.33	3.89	308.32	3	2	358
Cisplatin	84691	Approved	DNAdamage	1	Replication	Cl2H6N2Pt	300.051	1.99			1	1	573
CMK	NA	Experimental	RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA4, RPS6	6	Ser Thr Kinase	C17H17ClN4O2	344.795	35.76	11.08	292.08	5	2	358
Cyclopamine	442972	Experimental	SMO	1	Angiogenesis	C27H41NO2	411.6199	50.64		418.22	3	2	458
Cytarabine	6253	Approved	DNAsynthesis	1	Metabolism	C9H13N3O5	243.2166	22.21	6.64	201.26	7	4	576
Dasatinib	3062316	Approved	ABL1, ABL2, PDGFRB, FYN,	4	Receptor Tyrosine kinase	C22H26ClN7O2S	488.006	51.58	7.83	416.47	8	3	354
DMOG	560326	Experimental	P4HB	1	Transcription	C6H9NO5	175.1394	15.83		149.48	3	1	576
Docetaxel	148124	Approved	Microtubules	1	Mitosis	C43H53NO14	807.8792	82.06	4.04	734.12	10	5	576
Doxorubicin	31703	Approved	DNAintercalating	1	DNA repair	C27H29NO11	543.5193	53.87	9.06	462.89	12	6	667
EHT1864	NA	Experimental	RAC1	1	Cell cycle, Cytoskelton	C25H27F3N2O4S	508.553	50.33		433.79	6	0	354
Elesclomol	300471	Phase III	HSP70	1	Stress pathway	C19H20N4O2S2	400.518	40.64	3.88	348.09	2	2	358
Embelin	3218	Experimental	XIAP	1	Apoptosis	C17H26O4	294.3859	34.36	2.63	294.64	4	2	567
EpothiloneB	448013	Phase II	Microtubules	1	Cytoskelton, Cell cycle	C27H41NO6S	507.683	56.42	8.37	489.34	6	2	661
Erlotinib	176870	Approved	EGFR	1	Receptor Tyrosine kinase	C22H23N3O4	393.4357	43.48	10.36	358.74	7	1	482
Etoposide	36462	Approved	TOP2	1	DNA repair	C29H32O13	588.5566	58.77	2.99	496.33	12	3	576
FH535	3463933	Experimental	CTNNB1	1	Transcription	C13H10Cl2N2O4S	361.201	32.69		267.94	4	1	661
FTI277	3005532	Experimental	FNTA	1	Cell cycle	C22H29N3O3S2	447.614	49.75	9.65	408.39	4	4	661
GDC0449	24776445	Phase II	SMO	1	Angiogenesis	C19H14Cl2N2O3S	421.297	39.21	6.99	330.58	4	1	831
GDC0941	17755052	Phase I	PIK3CA, PIK3CB, PIK3CG, PIK3CD	4	Apoptosis	C23H27N7O3S2	513.636	54.38	9.72	432.56	8	1	667
Gefitinib	123631	Approved	EGFR	1	Receptor Tyrosine kinase	C22H24ClFN4O3	446.902	46.13	11.48	383.17	7	1	357
Gemcitabine	60750	Approved	DNAreplication	1	Replication	C9H11F2N3O4	263.1981	21.45	5.54	202.88	6	3	661
GNF2	5311510	Experimental	BCR-ABL	1	Tyrosine kinase,	C18H13F3N4O2	374.3166	34.68	9.2	297.55	5	2	661
GSK269962A	16095342	Experimental	ROCK1, ROCK2	2	Ser Thr Kinase	C29H30N8O5	570.5991	58.86	9.03	494.13	9	2	667
GSK650394	25022668	Experimental	SGK3	1	Stress pathway	C25H22N2O2	382.4544	42.81	3.82	346.82	3	2	563
GW441756	16219400	Experimental	NTRK1, ,	1	Tyrosine kinase	C17H13N3O	275.3046	29.91	6.41	237.49	2	1	531
GW843682X	15983966	Experimental	PLK1	1	Ser Thr Kinase	C27H28F3N5O2S	543.604	54.8	11.08	461.86	5	1	358
Imatinib	5291	Approved	KIT, RET, NTRK1, ABL1, PDGFRA, PDGFRB	6	Receptor Tyrosine kinase	C29H31N7O	493.6027	55.54	10.23	458	7	2	359
IPA3	521106	Experimental	PAK1	1	Ser Thr Kinase	C20H14O2S2	350.454	36.04		293.88	2	2	576
Irinotecan	60838	Approved	TOP1	1	DNA repair	C33H38N4O6	586.678	65.96	10.58	528.99	6	1	576
JNJ26854165	11609586	Phase I	MDM2	1	Apoptosis	C21H20N4	328.4103	39.79	12.57	302.97	3	3	496
JNK9L	NA	Experimental	MAPK8	1	Ser Thr Kinase	C26H27FN8O2	502.5434	53.01	8.4	434.15	9	1	661
JNKInhibitorVIII	11624601	Experimental	MAPK8	1	Ser Thr Kinase	C18H20N4O4	356.3758	36.69	7.12	318.71	7	2	661
JW7521	49836027	Experimental	MTOR	1	Ser Thr Kinase	C35H28F3N5O2	607.6243	60.79		515.91	5	0	361
KIN001135	11626927	Experimental	IKBKE	1	DNA repair	C22H19N3O5S2	469.533	47.75	12.84	385.66	7	0	317
KU55933	5278396	Experimental	ATM	1	Cell cycle	C21H17NO3S2	395.495	41.5		328.42	4	0	479
L685458	5479543	Experimental	PSENEN	1	Cell cycle, Apoptosis	C32H50N4O6	586.7626	65.12	6.2	582.02	5	5	667
Lapatinib	208908	Approved	EGFR, ERBB2	2	Tyrosine kinase	C29H26ClFN4O4S	581.058	61.19	11.58	482.69	7	2	358
LBW242	NA	Experimental	SMAC	1	Apoptosis	C27H42N4O2	454.648	52.79	10.92	459.52	4	2	573
Lenalidomide	216326	Approved	TNF	1	Angiogenesis	C13H13N3O3	259.2606	25.55	6.97	218.8	4	2	551
LFMA13	9549280	Experimental	BTK	1	Transcription	C11H8Br2N2O2	360.001	26.88		217.77	4	2	359
Metformin	4091	Approved	PRKAA1,	1	Metabolism	C4H11N5	129.1636	13.18		123.07	5	3	855
Methotrexate	126941	Approved	DHFR	1	Metabolism	C20H22N8O5	454.4393	44.54	3.56	384.14	12	5	576
MG132	462382	Experimental	Proteasome	1	Apoptosis	C26H41N3O5	475.6208	53.56	4.62	476.01	4	3	491
Midostaurin	24202429	Phase I	KIT	1	Receptor Tyrosine kinase	C35H30N4O4	570.6371	60.72	7.08	493.37	4	1	358
MitomycinC	5746	Approved	DNAcrosslinker	1	Replication	C15H18N4O5	334.3272	32.77	3.72	276.14	7	3	530
MK2206	46930998	Phase I	AKT1, AKT2	2	Ser Thr Kinase	C25H21N5O	407.4671	44.91	9.86	356.76	4	2	503
MS275	4261	Phase I	HDAC1, HDAC2, HDAC3	3	Chromatin	C21H20N4O3	376.4085	39.61	8.4	334.71	4	3	661
Nilotinib	644241	Approved	ABL1, KIT	2	Tyrosine kinase	C28H22F3N7O	529.5158	52.35	9.07	440.66	6	2	661
NSC87877	5459322	Experimental	PTPN6, PTPN11	2	Cell cycle	C19H13N3O7S2	459.452	44.31		348.18	10	3	354
NU7441	11327430	Experimental	PRKDC,	1	Ser Thr Kinase	C25H19NO3S	413.488	43.86	9.74	352.81	4	0	575
Nutlin3	11433190	Experimental	MDM2	1	Apoptosis	C30H30Cl2N4O4	581.49	60.09	8.45	497.18	5	1	667
NVPBEZ235	11977753	Phase I	PIK3CA, PIK3CB, PIK3CG, PIK3C, ,	4	Apoptosis	C30H23N5O	469.5365	51.35		417.7	4	0	544
NVPTAE684	16038120	Experimental	ALK	1	Receptor Tyrosine kinase	C30H40ClN7O3S	614.202	68.01	10.25	552.91	10	2	667
ObatoclaxMesylate	16727411	Phase I, Phase II	BCL2, BCLXL, MCL1	3	Apoptosis	C21H23N3O4S	413.49	37.51	8.74		3	2	551
OSI906	11640390	Phase I	IGF1R	1	Receptor Tyrosine kinase	C26H23N5O	421.4937	48.01	10.62	374	5	2	551
PAC1	6851947	Phase III	CASP3	1	Apoptosis	C23H28N4O2	392.494	44.61	9.52	372.47	5	2	361
Paclitaxel	36314	Approved	Microtubules, BCL2	2	Mitosis	C47H51NO14	853.9061	87.03	4.65	763.33	10	4	560
Panobinostat	6918837	Phase II	HDAC1	1	Chromatin	C21H23N3O2	349.4262	40.26	9.85	325.22	3	4	865
Parthenolide	5420805	Phase II	NFKB1	1	Apoptosis	C15H20O3	248.3175	27.05	3.31	243.4	2	0	479
Pazopanib	10113978	Approved	VEGFR, PDGFRA, PDGFRB, KIT	4	Receptor Tyrosine kinase, Angiogenesis	C21H23N7O2S	437.518	46.14	7.74	376.77	7	2	667
PD0325901	9826528	Phase I	MAP2K1, MAP2K2,	2	Ser Thr Kinase	C16H14F3IN2O4	482.193	37.96	4.47	311.06	5	4	996
PD0332991	5330286	Phase II	CDK4, CDK6	2	Cell cycle	C24H29N7O2	447.5328	49.06	10.09	406.94	8	2	1064
PD173074	1401	Experimental	FGFR1, FGFR3, SRC	3	Receptor Tyrosine kinase, Angiogenesis	C28H41N7O3	523.6702	60.46	10.91	507.12	8	3	661
PF02341066	11496366	Phase I	MET, ALK	2	Receptor Tyrosine kinase	C22H24Cl2FN5O	464.363	47.74		389.91	5	1	661
PF4708671	NA	Experimental	RPS6KB2	1	Ser Thr Kinase	C19H23F3N6	392.4213	37.18	11.64	336.94	6	1	358
PF562271	11713159	Experimental	PTK2	1	Tyrosine kinase	C21H20F3N7O3S	507.489	46.72	8.96	399.63	8	3	722
PHA665752	10461815	Experimental	MET	1	Receptor Tyrosine kinase	C32H34Cl2N4O4S	641.608	68.16	9.85	541.25	5	2	1057
PLX4720	24180719	Experimental	BRAF,	1	Ser Thr Kinase	C17H14ClF2N3O3S	413.826	38.12	4.42	316.23	4	2	964
Pyrimethamine	4993	Approved	DHFR	1	Metabolism	C12H13ClN4	248.711	25.79	12.5	213.77	4	2	864
QS11	NA	Experimental	ARFGAP1,	1	Apoptosis	C35H31N5O2	553.6529	60.41	8.25	497.91	5	2	1067
RAF265	11656518	Phase I	BRAFKDR	1	Ser Thr Kinase, Angiogenesis	C24H18F6N6O	520.4297	46.37	8.99	397.28	6	2	862
Rapamycin	5284616	Approved	MTOR	1	Ser Thr Kinase	C51H79NO13	914.1719	100.08	3.7	901.06	12	3	661
RDEA119	44182295	Phase I	MAP2K1, MAP2K2	2	Ser Thr Kinase	C19H20F3IN2O5S	572.337	46.57	2.25	384.57	6	4	500
RO3306	44450571	Experimental	CDK1	1	Ser Thr Kinase, Cell cycle	C18H13N3OS2	351.445	37.26	12.64	286.31	4	1	358
Roscovitine	160355	Phase I	CDK2	1	Cell cycle	C19H26N6O	354.4493	40.43	10.19	334.81	6	3	357
Salubrinal	5717801	Experimental	EIF2S1	1	Stress pathway, Apoptosis	C21H17Cl3N4OS	479.81	46.48	6.29	376.99	2	3	361
SB216763	176158	Experimental	GSK3A, GSK3B	2	Ser Thr Kinase	C21H16Cl2N2	367.271	38.24	12.39	305.13	1	1	661
SB590885	11316960	Experimental	BRAF	1	Ser Thr Kinase	C27H27N5O2	453.5356	52.25	9.6	406.94	6	2	460
Shikonin	5208	Phase II	CCR5	1		C16H16O5	288.2952	28.97	3.25	255.23	5	3	351
SL01011	14825856	Experimental	RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA4, RPS6	6	Ser Thr Kinase	C25H24O12	516.4509	49.94	1.25	430.91	10	4	553
Sorafenib	216239	Approved	PDGFRA, PDGFRB, KDR, KIT, FLT3	5	Ser Thr Kinase	C21H16ClF3N4O3	464.825	41.11	6.79	364	3	3	557
STritylLcysteine	76044	Experimental	KIF11	1	Cytoskelton	C22H21NO2S	363.473	39.42	5.74	333.89	3	2	560
Sunitinib	5329102	Approved	PDGFRA, PDGFRB, KDR, KIT, FLT3	5	Receptor Tyrosine kinase	C22H27FN4O2	398.4738	44.32	10.25	364.76	3	3	540
Temsirolimus	6918289	Approved	MTOR	1	Cell cycle, Angiogenesis	C56H87NO16	1030.2871	111.39	3.83	1005.82	14	4	569
Thapsigargin	446378	Experimental	ATP2A3	1	Cytoskelton	C34H50O12	650.7536	69.58	3.54	613.53	7	2	355
Tipifarnib	159324	Phase I	FNTA	1	Ser Thr Kinase	C27H22Cl2N4O	489.396	50.16		412.66	3	1	667
TKI258	44150621	Phase III	EGFR, FGFR1, PDGFRB, FLT1, KDR	5	Receptor Tyrosine kinase	C21H21FN6O	392.4294	42.38	8.28	338.2	5	2	860
Topotecan	60700	Approved	TOP1	1	DNA repair	C24H25N3O4	419.473	45.79	8.91	372.27	6	2	358
TW37	11455910	Experimental	BCL2	1	Apoptosis	C33H35NO6S	573.699	62.9	2.06	523.52	6	4	358
Vinblastine	6710780	Approved	Microtubules	1	Cytoskelton, Cell cycle	C46H58N4O9	810.9741	88.55	9.93	761.93	9	3	560
Vinorelbine	60780	Approved	Microtubules	1	Mitosis	C45H54N4O8	778.9323	85.08	9.84	716.82	8	2	479
Vorinostat	5311	Approved	HDAC1, HDAC2, HDAC3, HDAC6, HDAC8	5	Chromatin	C14H20N2O3	264.3202	28.39	2.69	253.81	3	3	576
VX680	5494449	Phase I	AURKA, AURKB, AURKC, FLT3, ABL1, JAK2	6	Cell cycle	C23H28N8OS	464.586	51.43	9.62	410.37	7	3	661
VX702	10341154	Phase II	MAPK11, MAPK12, MAPK13, MAPK14	4	Ser Thr Kinase, Apoptosis	C19H12F4N4O2	404.3178	34.7	6.49	311.46	3	2	865
WH4023	11844351	Experimental	SRC, ABL1	2	Tyrosine kinase	C32H36N6O4	568.666	62.01	11.16	523.24	9	1	661
WZ184	49821040	Experimental	BMX	1	Tyrosine kinase,	C23H28N8O2	448.5208	47.68	7.61	405.35	7	3	504
XMD885	46844147	Experimental	MAPK7	1	Ser Thr Kinase	C25H29N7O2	459.5435	51.17	10.68	418.77	8	1	358
ZD6474	3081361	Approved	RET, VEGFR2, EGFR	3	Receptor Tyrosine kinase, Angiogenesis	C22H24BrFN4O2	475.354	46.74	11.47	378.07	6	1	573
ZLLNleCHO	16760646	Experimental	PSENEN	1	Cell cycle	C26H41N3O5	475.6208	53.31	4.63	475.14	4	3	576
ZM447439	9914412	Experimental	AURKB	1	Ser Thr Kinase	C29H31N5O4	513.5875	57.58	9.61	465.27	8	2	667

CancerDR: Cancer Drug Resistance Database

CSIR - Indraprastha Institute of Information Technology, India

Home

General Information Submission Acknowledgement Guide Links Team Contact

Browsing of Anticancer Drugs